Article
Selective PPAR-α activation with pemafibrate attenuates macrophage-mediated progression of calcific aortic valve disease
2025-12-19
Abstract excerpt
<h4>BACKGROUND</h4> Calcific aortic valve disease (CAVD) compromises valve compliance and cardiac hemodynamics leading to aortic stenosis (AS) and cardiovascular dysfunction. With treatment for severe AS limited to valve replacement and no effective pharmacotherapies, new interventions are urgently needed for patients. This study evaluated pemafibrate, a selective peroxisome proliferator-activated receptor alpha...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 7db2c5de-b540-53e8-a696-8ecd95fa4a50
- DOI
- 10.64898/2025.12.17.694919
